Our results show that miR-575 expression increases significantly with the E2 treatment in a time-dependent manner and is transactivated by ERα in ER+ breast cancer, constituting a novel mechanism underlying the regulation of miRNA expression by estrogen. The gene discussed is ESR1; the disease is breast carcinoma.